Aptevo Therapeutics Inc. Share Price

Aptevo Therapeutics Inc. Share Price

NASDAQ: APVO | Micro Cap
$1.30
+$0.01 (0.78%) Last updated on 29 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Aptevo Therapeutics Inc. Stock Performance

Open
$1.33
Prev. Close
$1.29
Circuit Range
N/A
Day Range
$1.27 - $1.33
Year Range
$0.51 - $10.55
Volume
1,425
Average Traded
$1.29

Aptevo Therapeutics Inc. Share Price Today

As of 29 October 2026, Aptevo Therapeutics Inc.'s share price is $1.30. The stock opened at $1.33, compared to its previous close of $1.29. During today's trading session, Aptevo Therapeutics Inc.'s share price traded between $1.27 and $1.33, with an average price of $1.30. Over the past 52 weeks, the stock has recorded a high of $10.55 and a low of $0.51. In terms of performance, Aptevo Therapeutics Inc.'s share price has declined by 72.92% over the last six months and is down 15.58% on a year-on-year basis.

Aptevo Therapeutics Inc. Share Price Chart

Line chart of the Aptevo Therapeutics Inc. price trend over the selected period. The price rose overall, ranging from 1.32 to 1.32, ending at 1.32.
$1.27$1.33
L
Show Current Price
H

Aptevo Therapeutics Inc. Stock Fundamentals & Key Indicators

Market Cap
$410195.50
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-15.46
Revenue (TTM)
$0.00
Return On Equity (TTM)
-463.15%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
29.57%

Aptevo Therapeutics Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$9.03-$5.90-$6.70-$6.36
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A34.66%-13.56%5.07%

Aptevo Therapeutics Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$3.11$0.00$0.00$0.00
Net Profit$8.03-$17.41-$24.13-$27.54
Net Profit Margin258.20%N/AN/AN/A
Income ChangeN/A-316.81%-38.60%-14.13%

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Aptevo Therapeutics Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.80
$1.27
-31.35%
Sep 2026
$2.42
$1.85
-21.28%
Aug 2026
$3.92
$2.35
-43.31%
Jul 2026
$4.33
$4.14
-5.26%
Jun 2026
$5.00
$4.38
-10.90%
May 2026
$4.65
$4.91
+2.29%
Apr 2026
$4.11
$4.80
+13.21%
Mar 2026
$6.81
$4.24
-41.92%
Feb 2026
$7.63
$7.30
+0.69%
Jan 2026
$9.35
$7.25
-22.29%
Dec 2025
$1.37
$9.33
+578.55%
Nov 2025
$1.51
$1.38
-10.71%

APVO Share Price FAQs